• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For CME Group Stock Could Change Following Record October Volumes

    Simply Wall St·11/13/2026 17:13:47
    Listen to the news
    • CME Group declared a fourth quarter dividend of $1.30 per share, payable on December 30, 2026, to shareholders of record on December 11, 2026.
    • Record October trading activity in interest rate and U.S. Treasury contracts, together with new futures tied to NVIDIA H100 compute costs and single stocks, underscores how CME Group is leaning on product breadth and demand for risk management tools.
    • We will now look at how CME Group’s investment narrative could be influenced by record October volumes in core interest rate products.
    Spot emerging peers to CME Group that follow similar themes in rates, derivatives, and financial infrastructure by scanning our hand-picked 29 resilient stocks with low risk scores.

    CME Group Investment Narrative Recap

    CME Group appeals to shareholders who back a simple idea. You want a large derivatives platform that can keep attracting volume across interest rates, equities, commodities and crypto while running a high margin clearing and data franchise. The analyst consensus Narrative on Simply Wall St assumes earnings keep growing, with the focus on new contracts and technology projects actually being used by clients.

    Right now the key near term swing factor is how sustainable the recent record volumes in core rate products prove to be as macro expectations shift. The main risk is that competitors chip away at benchmark contracts in areas like energy and rates, or that regulatory outcomes on crypto and perpetual futures reduce how much value investors assign to newer products.

    The fourth quarter dividend affirmation of US$1.30 per share matters because it ties directly into CME Group’s appeal as an income and quality compounder. At the same time there is a flagged risk that the 3.6% yield is not well covered by free cash flow, which limits how much comfort investors can draw from the payout alone.

    Set that against a business generating US$6.96b of revenue and US$4.40b of net income with high reported margins. The picture is of a mature, cash generative exchange that still carries execution questions. Liquidity in new contracts like single stock and NVIDIA H100 compute futures, regulatory views on newer products and any shift in competitive share in key asset classes remain the catalysts to watch alongside the regular dividend stream.

    CME Group Analyst Assumptions In Focus

    CME Group’s current analyst blueprint leans heavily on a steady expansion of the top line and only a modest squeeze on profitability. Forecasts point to revenue growth of 6.1% per year over the next few years, while profit margins are expected to move from 63.3% today to 58.7% by 2029. That mix paints a picture of a business still growing in absolute profit dollars, even if each additional dollar of sales is modeled to be slightly less profitable.

    On earnings, the consensus view has CME Group generating US$4.4b of profit today and reaching US$4.9b by 2029. That is a US$0.5b uplift in earnings against the current base, with the share count assumed to drift lower by about 0.74% a year. For you as an investor, this framework implies analysts are counting on both the overall profit pool and per share earnings to trend higher, even with some trimming of margins in the model.

    Valuation work in the report ties these estimates into a 2029 snapshot where revenue is projected at US$8.3b and earnings at US$4.9b. The implied P/E multiple on those future profits sits at 28.5x, compared with about 25.0x on today’s earnings and roughly 38.1x for the broader US capital markets peer group. That set of assumptions effectively says CME Group could support a higher multiple than it currently carries, while still sitting below the level applied to the wider sector.

    CME Group's narrative projects US$8.3b revenue and US$4.9b earnings by 2029. This requires 6.1% yearly revenue growth and a US$0.5b earnings increase from US$4.4b today.

    Uncover why CME Group's fair value indicates that CME Group is fairly valued at its current price.

    NasdaqGS:CME 1-Year Stock Price Chart
    NasdaqGS:CME 1-Year Stock Price Chart

    Exploring Other Perspectives

    Three fair value views from the Simply Wall St Community cluster between US$258 and US$317 per share, which already shows how far opinions on CME Group can stretch. Put that next to catalysts such as new NVIDIA H100 compute futures and potential regulatory shifts in crypto and rates, and you have plenty of reasons to compare several alternative viewpoints before deciding how to frame CME Group in your own portfolio.

    Explore 2 other CME Group fair value estimates, including one that suggests it could be worth as much as $317.06.

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond CME Group?

    If CME Group helps anchor your watchlist but you want a few fresh angles to research alongside it, the Simply Wall St Screener offers a fast way to surface stocks that fit very different briefs, from income resilience to growth potential.